Skip to Content

VIRxSYS Corporation Demonstrates ?Functional Cure? and Survival Benefit for the simian model of HIV in Preclinical Vaccine Study

Results presented at AIDS Vaccine 2010 Conference

ATLANTA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Oct 1, 2010 - VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases, today presented results from a study of VRX1116, a simian analog for an investigational, lentiviral-based vaccine for HIV VRX1273, at the AIDS Vaccine 2010 conference in Atlanta, GA. In this prophylactic non human primate study, two out of five monkeys immunized with the vaccine were able to “functionally cure,” or fully control and suppress viral replication over time after challenge with a highly pathogenic simian immunodeficiency virus (SIV), and have shown stable or increased CD4 counts compared to pre-challenge baselines Additionally, the death of several monkeys in the control, unvaccinated group showed that VRX1116-based vaccination was capable of conferring a survival benefit following SIV infection. The vaccine was safely and repeatedly administered and proved to be highly immunogenic with sustained immune responses. Virological and immunological benefits, including control of viral load and preservation of the CD4 compartment, were sustained for as long as one year post-challenge.

"We and HIV key opinion leaders are very optimistic about these long-term results showing viral suppression, protection of the immune system and survival in this prophylactic study.” said Gary J. McGarrity, PhD, Executive Vice President of Scientific and Clinical Affairs at VIRxSYS Corporation. “In addition, the full control of SIV replication following infection of two of our monkeys is a significant milestone in our research to develop effective therapeutic and prophylactic vaccines for HIV.”

VIRxSYS' investigational VRX1273 vaccine is part of the company's work to create a therapeutic HIV vaccine to potentially lower HIV transmission rates and improve the lives of millions of individuals infected with HIV worldwide who – if they have access at all – must rely on expensive drugs associated with serious side effects to help control their infection. VIRxSYS is the only biotechnology company using lentiviral vectors to develop a therapeutic HIV vaccine.

AIDS Vaccine 2010 is being held September 28 - October 1, 2010 at the Omni Hotel in Atlanta, Georgia. The VRX1116 data was presented as “Highly immunogenic lentiviral vaccine provides control of viral load, preservation of the CD4 compartment, and survival advantage post-SIV challenge.”


Founded in 1998, VIRxSYS is a private biotechnology company that develops therapies for the treatment of serious human diseases utilizing its proprietary lentiviral vector and RNA reprogramming platforms. The Company exclusively licensed its patented lentiviral technology from The Johns Hopkins University and acquired its SMaRT™ RNA reprogramming technology from Intronn Inc. More information regarding VIRxSYS can be found at

About VIRxSYS' HIV Vaccine Program

VIRxSYS' lentiviral vector vaccine program is testing investigational HIV vaccine candidates for therapeutic and/or prophylactic use. The company's vaccine candidates against HIV are currently being evaluated in preclinical studies in non-human primates.


Contact: Corinth Group Communications
Russell LaMontagne, 917-744-7957


Posted: October 2010